Lexeo Therapeutics Inc
NASDAQ:LXEO
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
L
|
Lexeo Therapeutics Inc
NASDAQ:LXEO
|
557.6m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.1B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Lexeo Therapeutics Inc
Glance View
Lexeo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 53 full-time employees. The company went IPO on 2023-11-03. Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company. The firm has developed a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases that have unmet need and no approved treatments that address the underlying genetic cause of the disease. These programs include: LX2006, LX2020, LX2021, and LX2022. LX2006 is a gene therapy candidate designed to intravenously deliver a functional frataxin (FXN), a gene for the treatment of Friedreich’s ataxia (FA) cardiomyopathy. LX2020 is a gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the treatment of PKP2-ACM. LX2021 is a gene therapy candidate developing to intravenously deliver the coding sequence for the functional connexin 43 (Cx43) protein for a group of inherited cardiac muscle disorders. LX2022 delivers a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy (HCM).
